anlotinib + carboplatin + paclitaxel

This is a combination drug regimen consisting of **anlotinib**, **carboplatin**, and **paclitaxel**, used investigationally as a first-line or second-line therapy for certain advanced cancers, notably non-small cell lung cancer (NSCLC) and ovarian cancer. - **Anlotinib** is a small molecule multi-target receptor tyrosine kinase (RTK) inhibitor with anti-angiogenic and anti-tumor properties. It targets vascular endothelial growth factor receptors (VEGFR1/2/3), fibroblast growth factor receptors (FGFR1/2/3/4), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit, thereby inhibiting angiogenesis and tumor cell proliferation. - **Carboplatin** is a platinum-based chemotherapeutic agent that forms DNA cross-links, resulting in apoptosis of rapidly dividing tumor cells. - **Paclitaxel** is a microtubule-stabilizing agent that disrupts cell division and induces apoptosis by binding to tubulin. This combination, including maintenance therapy with anlotinib, is mainly being studied for efficacy and safety in patients with advanced or metastatic NSCLC (particularly EGFR/ALK wild-type non-squamous NSCLC) and advanced ovarian cancer, showing improved progression-free and overall survival versus historical chemotherapy controls[3][4][5].

Brand names

CatequentinibTaxolParaplatin

Other names

AL3818AL-3818AL 3818Catequentinib